预测司美格鲁肽对肥胖型2型糖尿病患者未达到血糖控制和减重双应答的可视化评分系统的建立与验证

孟凡东 ,  范静静 ,  刘馨 ,  孔璐璐

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1377 -1384.

PDF (1600KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1377 -1384. DOI: 10.12092/j.issn.1009-2501.2026.10.008

预测司美格鲁肽对肥胖型2型糖尿病患者未达到血糖控制和减重双应答的可视化评分系统的建立与验证

作者信息 +

Predicting dual response failure to semaglutide in obese type 2 dia-betes: development and validation of a visual scoring system

Author information +
文章历史 +
PDF (1637K)

摘要

目的: 构建司美格鲁肽对肥胖型 2 型糖尿 病(T2DM)患者未达到血糖控制和减重双应答 的风险列线图评分系统,并验证其预测效能。方 法:选取 2023 年 1 月至 2025 年 1 月于本院内分 泌科首次接受司美格鲁肽注射治疗的 347 例肥胖 型 T2DM 患者作为研究对象,根据时间分别将 2023 年 1 月至 2024 年 6 月和 2024 年 7 月至 2025 年 1 月选取的患者纳入到训练集(n=243) 和验证集(n=104)。根据双应答情况将训练 集患者分为应答组(n=159)和非应答组(n= 84)。使用单因素和多因素 Logistic 回归分析肥 胖型 T2DM 患者未达到血糖控制和减重双应答的 危险因素,并建立列线图评分系统。结果: BMI 较 低(OR:0.533,95%CI:0.381~0.748)、病程较长 (OR: 1.591, 95%CI: 1.294~ 1.957)、 空腹血糖 (fasting blood glucose, FBG)较低 (OR: 0.349, 95%CI:0.238~0.511)、HbA1c 较低(OR:0.380, 95%CI: 0.241~ 0.599)和内脏脂肪含量较低 (OR:0.989,95%CI:0.981~0.997)是司美格鲁肽 对肥胖型 T2DM 患者未达到血糖控制和减重双应 答的独立危险因素(P<0.05)。模型验证结果: 训练集和验证集的 Hosmer-Lemeshow 检验结果 分别为χ2 =12.463,P=0.132 和 χ2=7.753,P=0.445, 两集的校准曲线均趋近于理想曲线,ROC 曲线下 的 AUC 分别为 0.956(95%CI:0.940~0.971)和 0.814(95%CI: 0.790~ 0.838), 在 0%~ 100% 预 测范围内,模型的净获益值均>0。结论: BMI、病 程、FBG、HbA1c 和内脏脂肪含量与司美格鲁肽对 肥胖型 T2DM 患者血糖控制和减重双应答情况密 切相关,基于上述指标构建的列线图模型具有良 好的预测效能。

Abstract

AIM: To develop and validate a nomo- gram-based scoring system for predicting the risk of failing to achieve dual response in glycemic control and weight loss with semaglutide in obese type 2 di- abetes mellitus (T2DM) patients. METHODS: A total of 347 obese T2DM patients who received subcuta- neous semaglutide injection therapy for the first time at our endocrinology department between January 2023 and January 2025 were enrolled. Based on the treatment timeline, patients recruited from January 2023 to June 2024 were assigned to the training set (n=243), while those recruited from July 2024 to January 2025 were assigned to the vali- dation set (n=104). According to dual response sta- tus, patients in the training set were further divid- ed into a response group (n=159) and a non-re- sponse group (n=84). Univariate and multivariate logistic regression analyses were employed to iden- tify risk factors for failing to achieve the dual re- sponse, and a nomogram prediction model was constructed based on these factors. RESULTS: Low- er BMI (OR: 0.533, 95%CI: 0.381-0.748), longer du- ration of diabetes (OR: 1.591, 95%CI: 1.294-1.957), lower FBG (OR: 0.349, 95%CI: 0.238-0.511), lower HbA1c (OR: 0.380, 95%CI: 0.241-0.599), and lower visceral fat content (OR: 0.989, 95%CI: 0.981-0.997) were identified as independent risk factors for fail- ing to achieve the dual response (all P<0.05). Mod- el validation demonstrated good performance: Hos- mer-Lemeshow test results for the training and vali- dation sets were (χ2=12.463, P=0.132) and (χ2=7.753, P=0.445), respectively, indicating good calibration, which was further supported by calibra- tion curves closely aligning with the ideal line. The areas under the ROC curve (AUC) were 0.956 (95%CI: 0.940-0.971) for the training set and 0.814 (95%CI: 0.790-0.838) for the validation set. Deci- sion curve analysis showed positive net benefits across a threshold probability range of 0% to 100%. CONCLUSION: BMI, duration of diabetes, FBG, HbA1c, and visceral fat content are closely associat- ed with the likelihood of achieving dual response to semaglutide regarding glycemic control and weight loss in obese T2DM patients. The nomogram model constructed based on these indicators demon- strates good predictive performance.

关键词

司美格鲁肽 / 肥胖 / 2 型糖尿病 / 血糖控 制 / 减重 / 应答

Key words

semaglutide / obesity / type 2 diabetes mellitus / glycemic control / weight loss / response

引用本文

引用格式 ▾
孟凡东,范静静,刘馨,孔璐璐. 预测司美格鲁肽对肥胖型2型糖尿病患者未达到血糖控制和减重双应答的可视化评分系统的建立与验证[J]. 中国临床药理学与治疗学, 2026, 31(10): 1377-1384 DOI:10.12092/j.issn.1009-2501.2026.10.008

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

张思婷, 张继国, 贾小芳, 等. 2018 年中国 15 省份 18~65 岁居民肥胖与 2 型糖尿病患病的关联研究[J].中华流行病学杂志, 2022, 43(10): 1596-1602.

[2]

Liu Y, Luo X.New practice in semaglutide on type-2 dia- betes and obesity: clinical evidence and expectation[J].Front Med, 2022, 16(1): 17-24.

[3]

Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double- blind, double-dummy, placebo-controlled, phase 3 tri- al[J].Lancet, 2021, 397(10278): 971-984.

[4]

Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial[J].Lancet Diab En- docrinol, 2022, 10(3): 193-206.

[5]

Pérez-Belmonte LM, Sanz-Cánovas J, García de Lucas MD, et al. Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice[J].Front Endocrinol (Lausanne), 2022, 13: 851035.

[6]

Takahashi Y, Nomoto H, Yokoyama H, et al. Improve- ment of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcuta- neous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, par- allel-group comparison study (SWITCH-SEMA 1 study)[J].Diab Obes Metab, 2023, 25(6): 1503-1511.

[7]

中华医学会糖尿病学分会. 中国 2 型糖尿病防治指 南 (2020 年版)[J].中华糖尿病杂志, 2021, 13(4): 315-409.

[8]

Thewjitcharoen Y, Yenseung N, Butadej S, et al. Real- world use of once-weekly semaglutide in thai patients with type 2 diabetes mellitus in a private hospital set- ting[J].J ASEAN Fed Endocr Soc, 2023, 38(1): 21-28.

[9]

Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. Re- al-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observa- tional study[J].Prim Care Diabetes, 2021, 15(5): 871-878.

[10]

Garg SK, Kaur G, Haider Z, et al. Efficacy of semaglu- tide in overweight and obese patients with type 1 dia- betes[J].Diab Technol Ther, 2024, 26(3): 184-189.

[11]

叶惠成, 刘玉华, 尹沛锋, 等. 司美格鲁肽与利拉鲁肽 治疗肥胖型 2 型糖尿病患者疗效比较研究[J]. 临床 军医杂志,2023, 51(8): 840-842.

[12]

靳丽丽, 郄涛, 李立琴. 司美格鲁肽通过调控 AMPK/mTOR/ULK1 通路介导的自噬减轻缺氧/复氧 AC16 人心肌细胞炎症损伤[J]. 中国临床药理学与治 疗学,2025, 30(8): 1058-1066.

[13]

Kimura T, Katakura Y, Shimoda M, et al. Comparison of clinical efficacy and safety of weekly glucagon-like pep- tide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study)[J].Diabetes Obes Metab, 2023, 25(12): 3632-3647.

[14]

Frazer M, Swift C, Gronroos NN, et al. Real-world hemoglobin A1c changes, prescribing provider types, and medication dose among patients with type 2 dia- betes mellitus initiating treatment with oral semaglu- tide[J].Adv Ther, 2023, 40(11): 5102-5114.

[15]

Yabe D, Yamada Y, Kaku K, et al. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index[J].J Diabetes Investig, 2022, 13(7): 1161-1174.

[16]

Hansen KB, Svendstrup M, Lund A, et al. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out- patient clinic[J].Diabet Med, 2021, 38(10): e14655.

[17]

Melzer Cohen C, Mosenzon O, Aharonovich A, et al. Drug adherence, glycemic control, and weight reduc- tion with subcutaneous semaglutide in real-world management of type 2 diabetes[J].Diab Res Clin Pract, 2025, 222: 112086.

[18]

Cárdenas-Salas JJ, Sierra Poyatos RM, Luca BL, et al. RE- AL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: ambispective, multicen- ter clinical study. Results in the GLP1-experienced co- hort[J].J Diab Compl, 2024, 38(12): 108874.

[19]

Karagiannis T, Malandris K, Avgerinos I, et al. Subcuta- neously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials[J].Diabetologia, 2024, 67(7): 1206-1222.

[20]

Wolffenbuttel BHR, Brugts MP, Catarig AM, et al. Once-weekly semaglutide use in type 2 diabetes: real- world data from the SURE netherlands observational study[J].Adv Ther, 2023, 40(3): 920-933.

[21]

Menzen M, Berentzen TL, Catarig AM, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: re- sults from semaglutide real-world evidence (SURE) Germany[J].Exp Clin Endocrinol Diabetes, 2023, 131(4): 205-215.

[22]

Sherrill CH, Hwang AY.The pursuit of optimal semaglu- tide dosing in type 2 diabetes continues[J].Lancet, 2023, 402(10403): 668-669.

基金资助

国家自然科学基金(82403504)

AI Summary AI Mindmap
PDF (1600KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉